Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

571 articles

Research Review

Showing 1–3 of 3 articles · Keyword: Immunogenic cell death Clear keyword

Polymer science & technology (Washington, D.C.)2026ResearchDrug Delivery

1. Exosome-Coated Dendrimer Nanogels as a Therapeutic Vaccine for CT Imaging-Guided Chemoimmunotherapy of Pancreatic Cancer

Li Z, Xiao X, Li Y, Qin M, Xia L, Yang J, Et Al.

Development of new medicines that can treat pancreatic cancer with a sustained immune memory effect remains to be a challenging task. Herein, we report a tumor microenvironment-responsive dendrimer nanogel (DNG)-based therapeutic vaccine co-loaded with toyocamycin (Toy) and gold nanoparticles (Au NPs) and the surface…

Read the article

The Journal of pharmacology and experimental therapeutics2026ResearchNon-viral Gene DeliveryDrug Delivery

2. Bioactivatable conjugated nanocarriers for synergistic mRNA-mediated cancer immunotherapy

Nazir N, Gajjar Tb, Hanumanthayya M, Bainsal N, Singhal D, Smerat A, Et Al.

mRNA immunotherapy holds transformative potential in oncology, yet single-agent approaches frequently fail against immunosuppressive tumor microenvironments (TMEs). Bioactivatable co-delivery of immunogenic chemotherapy alongside mRNA offers mechanistically synergistic advantages, yet coformulation of hydrophobic…

Read the article

ACS nano2026ResearchNon-viral Gene DeliveryDrug Delivery

3. Oncolytic Virus-like Nanoparticle Targets the Golgi Apparatus via Sphingomyelin

He L, Yang L, Ren M, Wang J, Zhao W, Yang C, Et Al.

The Golgi apparatus (GA) has emerged as a promising target for cancer therapy. Commonly, therapeutics are guided to the GA by recognizing specific receptors on the GA membrane. However, the low and heterogeneous expression of these receptors often results in suboptimal targeting efficiency. Here, we present an…

Read the article

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.